- Press Release Distribution

Scientists model 'true prevalence' of COVID-19 throughout pandemic

Scientists model 'true prevalence' of COVID-19 throughout pandemic
( Government officials and policymakers have tried to use numbers to grasp COVID-19's impact. Figures like the number of hospitalizations or deaths reflect part of this burden. Each datapoint tells only part of the story. But no one figure describes the true pervasiveness of the novel coronavirus by revealing the number of people actually infected at a given time -- an important figure to help scientists understand if herd immunity can be reached, even with vaccinations.

Now, two University of Washington scientists have developed a statistical framework that incorporates key COVID-19 data -- such as case counts and deaths due to COVID-19 -- to model the true prevalence of this disease in the United States and individual states. Their approach, published the week of July 26 in the Proceedings of the National Academy of Sciences, projects that in the U.S. as many as 60% of COVID-19 cases went undetected as of March 7, 2021, the last date for which the dataset they employed is available.

This framework could help officials determine the true burden of disease in their region -- both diagnosed and undiagnosed -- and direct resources accordingly, said the researchers.

"There are all sorts of different data sources we can draw on to understand the COVID-19 pandemic -- the number of hospitalizations in a state, or the number of tests that come back positive. But each source of data has its own flaws that would give a biased picture of what's really going on," said senior author Adrian Raftery, a UW professor of sociology and of statistics. "What we wanted to do is to develop a framework that corrects the flaws in multiple data sources and draws on their strengths to give us an idea of COVID-19's prevalence in a region, a state or the country as a whole."

Data sources can be biased in different ways. For example, one widely cited COVID-19 statistic is the proportion of test results in a region or state that come back positive. But since access to tests, and a willingness to be tested, vary by location, that figure alone cannot provide a clear picture of COVID-19's prevalence, said Raftery.

Other statistical methods often try to correct the bias in one data source to model the true prevalence of disease in a region. For their approach, Raftery and lead author Nicholas Irons, a UW doctoral student in statistics, incorporated three factors: the number of confirmed COVID-19 cases, the number of deaths due to COVID-19 and the number of COVID-19 tests administered each day as reported by the COVID Tracking Project. In addition, they incorporated results from random COVID-19 testing of Indiana and Ohio residents as an "anchor" for their method.

The researchers used their framework to model COVID-19 prevalence in the U.S. and each of the states up through March 7, 2021. On that date, according to their framework, an estimated 19.7% of U.S. residents, or about 65 million people, had been infected. This indicates that the U.S. is unlikely to reach herd immunity without its ongoing vaccination campaign, Raftery and Irons said. In addition, the U.S. had an undercount factor of 2.3, the researchers found, which means that only about 1 in 2.3 COVID-19 cases were being confirmed through testing. Put another way, some 60% of cases were not counted at all.

This COVID-19 undercount rate also varied widely by state, and could have multiple causes, according to Irons.

"It can depend on the severity of the pandemic and the amount of testing in that state," said Irons. "If you have a state with severe pandemic but limited testing, the undercount can be very high, and you're missing the vast majority of infections that are occurring. Or, you could have a situation where testing is widespread and the pandemic is not as severe. There, the undercount rate would be lower."

In addition, the undercount factor fluctuated by state or region as the pandemic progressed due to differences in access to medical care among regions, changes in the availability of tests and other factors, Raftery said.

With the true prevalence of COVID-19, Raftery and Irons calculated other useful figures for states, such as the infection fatality rate, which is the percentage of infected people who had succumbed to COVID-19, as well as the cumulative incidence, which is the percentage of a state's population who have had COVID-19.

Ideally, regular random testing of individuals would show the level of infection in a state, region or even nationally, said Raftery. But in the COVID-19 pandemic, only Indiana and Ohio conducted random viral testing of residents, datasets that were critical in helping the researchers develop their framework. In the absence of widespread random testing, this new method could help officials assess the true burden of disease in this pandemic and the next one.

"We think this tool can make a difference by giving the people in charge a more accurate picture of how many people are infected, and what fraction of them are being missed by current testing and treatment efforts," said Raftery.


The research was funded by the National Institutes of Health.

For more information, contact Raftery at

Link to dashboard created by Irons and Raftery: "COVID Infections in the United States,"

Link to past coverage: July 30, 2020, "National Academies publishes guide to help public officials make sense of COVID-19 data,"

LIST (below) of the COVID-19 infection fatality rate, cumulative incidence and undercount factors (respectively) for U.S. states and Washington, D.C., as of March 7, 2021. Figures are the posterior median, with the 95% confidence intervals indicated in parentheses. Credit: Irons and Raftery, PNAS, 2021.

State/Territory: Infection Fatality Rate, Cumulative Incidence, Undercount Factor Alabama: 0.90% (0.70-1.15), 24.0% (18.8-30.6), 2.4 (1.8-3.0) Alaska: 0.35% (0.28-0.43), 11.8% (10.1-14.2), 1.5 (1.3-1.8) Arizona: 0.93% (0.75-1.14), 24.5% (20.1-30.3), 2.2 (1.8-2.7) Arkansas: 0.78% (0.64-0.95), 23.2% (19.2-28.4), 2.2 (1.8-2.7) California: 0.88% (0.70-1.09), 16.9% (13.6-20.9), 1.9 (1.6-2.4) Colorado: 0.60% (0.49-0.71), 17.2% (14.6-20.9), 2.3 (2.0-2.8) Connecticut: 1.37% (1.10-1.70) 15.9% (12.9-19.9) 2.0 (1.6-2.5) Delaware: 0.92% (0.74-1.13), 17.0% (14.0-21.0), 1.9 (1.6-2.3) Florida: 0.78% (0.64-0.94), 19.5% (16.3-23.8), 2.2 (1.9-2.8) Georgia: 0.67% (0.54-0.82), 25.9% (21.4-32.0), 2.7 (2.2-3.4) Hawaii: 0.70% (0.54-0.91), 4.6% (3.6-5.8), 2.3 (1.8-2.9) Idaho: 0.28% (0.23-0.33), 37.8% (32.1-45.9), 4.0 (3.4-4.8) Illinois: 0.96% (0.78-1.16), 19.3% (16.1-23.7), 2.0 (1.7-2.5) Indiana: 0.84% (0.70-1.00), 22.9% (19.2-27.6), 2.3 (1.9-2.8) Iowa: 0.76% (0.61-0.97), 23.6% (18.7-29.5), 2.6 (2.1-3.3) Kansas: 0.59% (0.47-0.75), 28.6% (22.6-36.1), 2.8 (2.2-3.5) Kentucky: 0.53% (0.43-0.63), 21.4% (18.0-25.8), 2.3 (2.0-2.8) Louisiana: 1.01% (0.82-1.22), 21.1% (17.5-26.1), 2.3 (1.9-2.8) Maine: 0.73% (0.60-0.87), 7.3% (6.2-8.8), 2.1 (1.8-2.6) Maryland: 0.94% (0.77-1.15), 13.9% (11.5-17.1), 2.2 (1.8-2.7) Massachusetts: 1.71% (1.36-2.13), 14.4% (11.6-18.0), 1.7 (1.4-2.1) Michigan: 1.00% (0.77-1.29), 17.1% (13.3-22.1), 2.6 (2.0-3.4) Minnesota: 0.64% (0.52-0.76), 18.4% (15.4-22.4), 2.1 (1.8-2.6) Mississippi: 0.74% (0.61-0.89), 31.6% (26.6-38.6), 3.2 (2.7-3.9) Missouri: 0.69% (0.55-0.87), 19.6% (15.8-24.7), 2.5 (2.0-3.2) Montana: 0.62% (0.50-0.75), 21.0% (17.5-25.5), 2.3 (1.9-2.8) Nebraska: 0.53% (0.43-0.64), 21.1% (17.7-25.7), 2.0 (1.7-2.5) Nevada: 0.73% (0.59-0.87), 22.5% (18.8-27.5), 2.4 (2.0-2.9) New Hampshire: 0.66% (0.54-0.79), 13.4% (11.3-16.2), 2.4 (2.0-2.9) New Jersey: 1.22% (0.97-1.53), 22.2% (17.7-28.0), 2.4 (1.9-3.1) New Mexico: 1.01% (0.83-1.21) 18.6% (15.6-22.7) 2.1 (1.8-2.5) New York: 1.12% (0.87-1.42), 18.6% (14.7-23.9), 2.1 (1.7-2.8) North Carolina: 0.58% (0.48-0.68), 19.4% (16.5-23.4), 2.4 (2.0-2.8) North Dakota:, 0.86% (0.71-1.03), 22.4% (19.0-27.1), 1.7 (1.4-2.0) Ohio: 0.83% (0.68-1.03), 19.5% (15.9-23.7), 2.3 (1.9-2.9) Oklahoma: 0.47% (0.38-0.56), 25.1% (21.1-30.6), 2.3 (1.9-2.8) Oregon: 0.69% (0.55-0.85), 8.2% (6.7-10.0), 2.2 (1.8-2.8) Pennsylvania: 1.00% (0.82-1.19), 19.4% (16.4-23.7), 2.6 (2.2-3.2) Rhode Island: 1.41% (1.14-1.72), 17.4% (14.3-21.4), 1.4 (1.2-1.8) South Carolina: 0.76% (0.63-0.91), 23.0% (19.4-28.0), 2.3 (1.9-2.8) South Dakota: 0.68% (0.56-0.82), 31.2% (26.1-37.9), 2.5 (2.1-3.0) Tennessee: 0.79% (0.64-0.97), 21.8% (17.7-26.9), 1.9 (1.6-2.4) Texas: 0.70% (0.57-0.85), 22.7% (18.8-27.8), 2.5 (2.1-3.0) Utah: 0.22% (0.18-0.26), 28.0% (23.8-33.7), 2.5 (2.1-3.0) Vermont: 0.72% (0.57-0.92), 4.6% (3.8-5.6), 1.8 (1.5-2.2) Virginia: 1.53% (1.09-2.36), 8.3% (5.5-11.7), 1.2 (0.8-1.7) Washington: 0.51% (0.41-0.64), 12.9% (10.3-16.1), 2.9 (2.3-3.6) West Virginia: 0.86% (0.71-1.01), 15.4% (13.2-18.5), 2.0 (1.8-2.5) Wisconsin: 0.57% (0.46-0.69), 21.5% (17.9-26.6), 2.0 (1.7-2.5) Wyoming: 0.58% (0.46-0.71), 21.0% (17.3-25.9), 2.2 (1.8-2.7) Washington, D.C.: 1.19% (0.94-1.49), 12.2% (9.8-15.3), 2.1 (1.7-2.7)

[Attachments] See images for this press release:
Scientists model 'true prevalence' of COVID-19 throughout pandemic


New breakthrough to help immune systems in the fight against cancer

New breakthrough to help immune systems in the fight against cancer
New research has identified potential treatment that could improve the human immune system's ability to search out and destroy cancer cells within the body. Scientists have identified a way to restrict the activity of a group of cells which regulate the immune system, which in turn can unleash other immune cells to attack tumours in cancer patients. "A patient's immune system is more than able to detect and remove cancer cells and immunotherapy has recently emerged as a novel therapy for many different types of cancers." Explained Nullin Divecha, Professor of Cell Signalling at the University of Southampton who led the study. "However, cancer cells can generate a microenvironment ...

Through the thin-film glass, researchers spot a new liquid phase

Research published in the Proceedings of the National Academy of Sciences describes a new type of liquid in thin films, which forms a high-density glass. Results generated in this study, conducted by researchers in Penn's Department of Chemistry, demonstrate how these glasses and other similar materials can be fabricated to be denser and more stable, providing a framework for developing new applications and devices through better design. Glass is typically created through solidification, or falling out of equilibrium, of a liquid when it is cooled to a temperature where its motion arrests. The structure of a glass closely ...

Administering opioids to pregnant mice alters behavior and gene expression in offspring

Administering opioids to pregnant mice alters behavior and gene expression in offspring
Mice exposed to the opioid oxycodone before birth experience permanent changes in behavior and gene expression. The new research published in eNeuro highlights a need to develop safer types of painkillers for pregnant women. Opioids like oxycodone are prescribed to pregnant women to treat pain, but the drugs may affect the fetus, too. Opioids can pass through the placenta, binding to receptors in the fetal brain, which can lead to opioid withdrawal in newborn babies. The long-term consequences of prenatal opioid exposure haven't been fully studied, however. To explore this, Martin et al. administered oxycodone to female mice every day for the two weeks prior ...

Brain's 'memory center' needed to recognize image sequences but not single sights

Brains memory center needed to recognize image sequences but not single sights
A new MIT study of how a mammalian brain remembers what it sees shows that while individual images are stored in the visual cortex, the ability to recognize a sequence of sights critically depends on guidance from the hippocampus, a deeper structure strongly associated with memory but shrouded in mystery about exactly how. By suggesting that the hippocampus isn't needed for basic storage of images so much as identifying the chronological relationship they may have, the new research published in Current Biology can bring neuroscientists closer to understanding how the brain coordinates long-term visual memory across key regions. "This offers the ...

Safety of second dose of mRNA COVID-19 vaccines after first-dose allergic reactions

What The Study Did: Researchers examined the safety of the second dose of the Pfizer-BioNTech or Moderna COVID-19 vaccines in patients who experienced an allergic reaction to the first dose. Authors: Kimberly G. Blumenthal, M.D., M.Sc., of Massachusetts General Hospital in Boston, is the corresponding author. To access the embargoed study: Visit our For The Media website at this link (doi:10.1001/jamainternmed.2021.3779) Editor's Note: The article includes conflicts of interest and funding and support disclosures. ...

Changes in disparities in access to care, health after Medicare eligibility

What The Study Did: The association between Medicare eligibility at age 65 and changes in racial and ethnic disparities in access to care and self-reported health was evaluated in this study. Authors: Jacob Wallace, Ph.D., of the Yale School of Public Health in New Haven, Connecticut, is the corresponding author. To access the embargoed study: Visit our For The Media website at this link (doi:10.1001/jamainternmed.2021.3922) Editor's Note: The article includes conflicts of interest and funding and support disclosures. Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support. INFORMATION: Media advisory: The full study and ...

Use of high-risk medications among lonely older adults

What The Study Did: Survey data were used to investigate the relationship between loneliness and high-risk medication use in adults older than age 65. Authors: Ashwin A. Kotwal, M.D., M.S., of the University of California, San Francisco School of Medicine, is the corresponding author. To access the embargoed study: Visit our For The Media website at this link (doi:10.1001/jamainternmed.2021.3775) Editor's Note: The article includes conflicts of interest and funding and support disclosures. Please see the article for additional information, including other authors, author contributions ...

65+ and lonely? Don't talk to your doctor about another prescription

Lonely, older adults are nearly twice as likely to use opioids to ease pain and two-and-a-half times more likely to use sedatives and anti-anxiety medications, putting themselves at risk for drug dependency, impaired attention, falls and other accidents, and further cognitive impairment, according to a study by researchers at UC San Francisco. The study found that just over half of 6,000 respondents in a nationally representative survey of seniors living independently were not lonely, while 40 percent were moderately lonely, and 7 percent were highly lonely. The proportion of seniors ...

Exosome formulation developed to deliver antibodies for choroidal neovascularization therapy

Exosome formulation developed to deliver antibodies for choroidal neovascularization therapy
Researchers from the Institute of Process Engineering (IPE) of the Chinese Academy of Sciences, Beijing Chaoyang Hospital and the University of Queensland have developed a new formulation based on regulatory T-cell exosomes (rEXS) to deliver vascular endothelial growth factor (VEGF) antibodies for choroidal neovascularization therapy. The study was published in Nature Biomedical Engineering on July 26. Ocular neovascularization is often associated with age-related macular degeneration, diabetic retinopathy and other ocular diseases, which can cause severe vision loss. The present treatment for ocular neovascular disease in clinic is intravitreal injection of VEGF antibodies (aV) to block the activity of VEGF ...

Second COVID-19 mRNA vaccine dose found safe following allergic reactions to first dose

BOSTON - In a multi-hospital analysis of individuals who experienced an allergic reaction to their first mRNA COVID-19 vaccine dose, all patients who went on to receive a second dose tolerated it without complications. The research, which was led by allergists at Massachusetts General Hospital (MGH) and is published in JAMA Internal Medicine, indicates that a first dose reaction to COVID-19 vaccination should not keep people from getting a second dose. Allergic reactions after mRNA COVID-19 vaccinations have been reported to be as high as 2%, with anaphylaxis--a life-threatening whole-body allergic reaction--occurring in up to 2.5 per 10,000 people. ...


Making table tennis accessible for blind players #Acoustics23

Twice daily electrical stimulation may boost mental processes in Alzheimer’s disease

Young age at first menstrual cycle linked to heightened diabetes risk in mid-life

State abortion access key factor in future US doctors’ training (residency) choices

Tobacco related annual medical spend of US Minorities who smoke double that of White peers

Singing in the rain: Why the bundengan sounds better wet #Acoustics23

Limitations of asteroid crater lakes as climate archives

AAAS announces addition of Biomaterials Research to Science Partner Journal program

Picking up good vibrations: The surprising physics of the didjeridu #Acoustics23

Bacteria's mucus maneuvers: Study reveals how snot facilitates infection

Shuqing Xu receives ERC Consolidator Grant for his research on the evolution in ecological communities in response to climate change

Study of sourdough starter microbiomes to boost bread quality and safety

UT receives National Institute of Justice awards for forensics research

Newly identified biomarkers may detect early cognitive decline via blood test

Researchers predict climate change-driven reduction in beneficial plant microbes

Addicted to your phone? New tool identifies overuse of digital media

International consensus report on gaps and opportunities for the clinical translation of precision diabetes medicine

Depression, constipation, and urinary tract infections may precede MS diagnosis

Chemists create organic molecules in a rainbow of colors

NCCN summit navigates solutions for financial and other cancer-related hardships

Incarcerated women punished at higher rates for minor infractions than men, UTEP study shows

Conference on microplastics in water: characterization, cure and prevention

Dorothee Dormann receives an ERC Consolidator Grant to support her research into neurodegenerative diseases

Reducing the energy consumption of software: Sebastian Erdweg receives ERC Consolidator Grant

Study finds plant nurseries are exacerbating the climate-driven spread of 80% of invasive species

Jefferson Lab site grows with addition of Applied Research Center

Texas A&M receives $1.8 million NIH grant to support bone health in people with down syndrome

Membrane raft redox signaling contributes to visfatin-induced inflammation and kidney damage

New study highlights COVID-19’s adaptive strategy for infection

Type 1 diabetes: B cell-derived natural antibodies suppress autoimmune pathogenesis

[] Scientists model 'true prevalence' of COVID-19 throughout pandemic